UBS Oncology Impact Fund L.P., 10% Owner at Werewolf Therapeutics, Inc. (HOWL), sold 417,794 shares at $1.72 ($685K) on 2025-10-27, disclosed to the SEC on 2025-10-29.
Scheduled sale ($685k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.72 | 72,709 | $125K | 18.3% |
| 2 | $1.72 | 72,709 | $125K | 18.3% |
| 3 | $1.64 | 69,068 | $113K | 16.5% |
| 4 | $1.64 | 69,068 | $113K | 16.5% |
| 5 | $1.55 | 134,240 | $208K | 30.4% |
| Total | $1.64 avg | 417,794 |
| $685K |
| 100% |
| Filing → |
| ITOS | SELL | 2021-09-27 | $3.2M | — | Filing → |
| CGEM | SELL | 2021-09-02 | $1.3M | — | Filing → |
| HARP | SELL | 2021-05-24 | $541K | — | Filing → |